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of the case mix of the hospital activity. As a consequence, it could be a useful model 
to increase the awareness of the economic impact and to allow a more informed 
management at hospital and regional level.
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Objectives: The aim of our study is to analyze the costs incurred by hospitalized 
patients in 2010, in the intensive care unit (ICU) of San Leonardo Hospital (Southern-
Italy). MethOds: A retrospective cost analysis was performed on patients with a 
length of stay longer than 24 hours. Direct medical costs were estimated (hospi-
talization, surgical procedures, devices). The costs of hospitalizations and surgical 
procedures were calculated based on the 24.0 version of the tariff system DRG 
(Diagnosis Related Group). The data on the costs of the devices were provided by 
the management of the hospital pharmacy. To evaluate the burden of the diagnostic 
groups two indicators were used: cost per surviving patient (total resources used / 
total survivors) and money loss per patient (total resources used for dead patients 
/ total patients) [Rossi et al. Intensive Care Med. 2006]. Results: A total of 201 
patients hospitalized in the ICU in 2010 were selected and analyzed depending on 
their diagnostic group. Hospitalized patients who had a hospital stay longer than 
or equal to 24 hours, were 95% of the sample. Most frequent diagnostic groups have 
been: edema (16.4%), left heart failure (13.9%) and COPD (9.0%). There is a wide vari-
ation between the average costs per patient probably due to the difference in the 
duration of hospitalization (from a minimum of € 2,777 in stroke, to a maximum 
of 7,227 euros in nephro-urological disease). Intracranial bleeding is the disease 
causing the highest costs per dead or survived patient. The nephro-urological and 
neurological diseases are characterized by the lowest costs, for dead and survived 
patients, indicating a better efficiency. cOnclusiOns: The results are a starting 
point for further investigations aimed at the exploitation of resources absorbed 
by ICU opposed to the need to provide patients with the best possible health care.
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Objectives: Medical nutrition (MN) targets patients with malnutrition or with 
specific disease such as Crohn’s disease (CD) to support their recovery. Efficacy of 
MN has been demonstrated in malnutrition, as well as in paediatric CD or gastro-
intestinal (GI) cancer surgery. However, its health economic evidence is less known. 
This article summarizes the findings of a systematic literature search on health 
economics evidence of MN in order to understand what the value for money of 
MN interventions is. MethOds: A systematic literature search was performed to 
identify publications related to health economics evidence of MN. The result of it 
was communicated elsewhere. For selected articles, the clinical background, basis 
of the analysis, health economic design and results were extracted and summa-
rized by relevant disease areas. Results: Among the 32 articles found, 11 covered 
malnutrition, 9 related to GI surgery, 6 studied cow milk allergies (CMA), whereas 
the remaining focused on various diseases. When targeting malnutrition, MN was 
accepted as being cost-effective and/or cost-savings from budget impact analyses. 
In GI surgery, when taking into account the full episode of care, oral and enteral 
nutrition was assessed as good value-for-money. In CMA, there was a significant 
health care budget impact of using MN to treat symptoms of this allergy. In the 
remaining indications, the use of enteral tube feeding was demonstrated as being 
cost-saving compared to parenteral nutrition. cOnclusiOns: Based on a system-
atic literature search, MN interventions showed value for money in different health 
care settings. Although few studies calculated an incremental cost-effectiveness 
ratio (ICER), those calculated were all below thresholds applied in medical settings. 
In addition, most of the times MN was more effective and cost saving, thus a domi-
nant option. However, more research is needed to strengthen economic modelling 
for medical nutrition interventions.
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Objectives: To assess the impact of recently published (2011) Guidelines for 
Pharmacoeconomic Evaluations for Serbia and ISPOR Guidelines (2013) on the 
methods and the conduct of budget impact analysis (BIA) during reimbursement 
submission. MethOds: We investigated how many reimbursement submissions 
were made with an accompanying BIA to the Health Insurance Fund in Serbia from 
2012 till June 2013. Results: There were 306 submissions in 2012 and 2013 and none 
of those had a thorough and complete BIA submitted. There were 65 new drugs 
(international non-proprietary names (INNs)) added to the Reimbursement list in 
2012 and 5 new drugs (INNs) in April 2013. Possible reason for a non-complete BIAs 
was that it is not an obligatory part of the submission dossier. It is recommended 
at this moment, but the plan is to make it an obligatory part. BIA simply quantifies 
the financial consequences of using health-care services, comparing reference with 
anticipated scenario. Currently there is no template for the BIA, just recommenda-
tions how to address time horizon, target population, costing, scenarios and dis-
counting. This could be one of the reasons why most of the submissions had almost 
complete pharmacoeconomics evaluation. cOnclusiOns: The availability of a 
template for BIA would increase transparency, the quality of submissions and pro-
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Contrast-induced nephropathy (CIN) is a clinically significant and costly com-
plication related to the use of iodine-based contrast media (CM). The hypothesis 
regarding the advantages of isoosmolar CM compared to low-osmolar CM was not 
confirmed in recent meta-analyses; still, there may be safety differences between 
individual CM. Objectives: To perform a pharmacoeconomic comparison of the 
CM ioversol and iohexol used for x-ray procedures in Russia. MethOds: We cal-
culated the costs for using ioversol and iohexol taking into account the risk of 
the occurrence of CIN and CIN-associated complications. Data for the model were 
extracted from published clinical trials and reviews. We performed an indirect com-
parison of both CM to calculate the relative risk (RR) of CIN (via the CM iodixanol as 
a mutual control). This RR value was used in the model to simulate the impact of 
potential safety differences between both CM on the costs. Direct medical costs were 
calculated based on the Russian health care system setting. Related costs for CM 
and for CIN-associated complications (e.g. cardiovascular complications, respiratory 
distress syndrome and hemodialysis for acute kidney injury) were also taken into 
account. Cost calculations were performed separately for patients with low, medium 
and high risk for CIN. One-way sensitivity analysis was performed. Results: RR of 
CIN was 0.26 (95% confidence interval 0.12-0.58) for ioversol vs iohexol in the indirect 
comparison. Direct medical costs were higher for iohexol than for ioversol due to 
the slightly higher rate of CIN, thus, CIN-associated complications: net benefits 
were 469.16; 752.88 and 3313.13 rubles (~11.03; 17.70; 77.91 Euros) per patient with 
low, medium and high risk of CIN correspondingly. Still, results were sensitive to 
the price of both CM. cOnclusiOns: In the Russian health care setting, the use 
of ioversol seems to be more cost efficient than iohexol due to slightly favorable 
renal safety.
PHP88
eConomiC evAlUAtion of intrAvenoUs iodinAted ContrAst mediA in 
itAly
Iannazzo S.1, Vandekerckhove S.2, De Francesco M.1, Nayak A.3, Morana G.4, Valentino M.5, 
Ronco C.3
1IMS Health, Milan, Italy, 2IMS Health HEOR, Vilvoorde, Belgium, 3San Bortolo Hospital, Vicenza, 
Italy, 4Ca’ Foncello Hospital, Treviso, Italy, 5S. Antonio Abate Hospital, Tolmezzo, Italy
Objectives: Contrast-induced acute kidney injury (CI-AKI) is defined as a dete-
rioration in renal function after administration of radiologic iodinated contrast 
media (CM). Iodixanol, showed a lower CI-AKI incidence than low-osmolar contract 
media (LOCM). A cost-effectiveness analysis was performed comparing iodixanol 
and LOCM in intravenous (IV) setting in Italy. MethOds: A Markov model was 
developed. Patients moved across four health states, CI-AKI free, CI-AKI, myocar-
dial infarction and death. The simulation horizon was lifetime with one-month 
cycles. Costs and outcomes were discounted at 3.5% rate. CI-AKI incidence was 
considered from published literature across different definitions. Cost-effectiveness 
of iodixanol was assessed in terms of incremental cost per life year gained. Net 
monetary benefit (NMB) was also calculated. Both deterministic and probabilistic 
sensitivity analysis were performed. Results: Base-case results showed an aver-
age survival increase of 0.51 LYs and a saving of € 7.25 for iodixanol vs. LOCM. The 
cost-effectiveness of iodixanol was confirmed when other scenarios were explored, 
such as varying CI-AKI definition, sub-populations with specified risk factors, CM 
hospital bids prices and inclusion of adverse drug reactions of allergic nature. A NMB 
ranging between € 6,007.25 and € 30,007.25 was calculated. cOnclusiOns: base-
case results are showing that IV iodixanol is cost-effective compared to LOCM in 
the Italian clinical setting of hospital CT radiology practice. However, some caution 
is due, mainly linked to inherent limitations of the modelling technique and to the 
lack of agreement on CI-AKI incidence data in the clinical literature.
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Objectives: The Italian National Health Service (Servizio Sanitario Nazionale-SSN)is 
financed at hospital level by DRG (Diagnosis Related Group): the classification is 
defined at national level and the tariffs at regional level. Each region could define 
different tariffs for different types of hospital, choosing different criteria to identify 
them. The aim of this study is to analyze the incidence of the different types of 
costs for different surgical procedures and to evaluate the impact of the case mix 
on the total hospital costs. MethOds: We developed an excel model, the Win-Win, 
in order to analyze the incidence of different types of costs using the hospital per-
spective: length of stay, operating room time, personnel, materials. We identified 8 
surgical procedures, based on the International Classification of Disease 9-Clinical 
Modification, and for each one, we collected all the data from a survey based on 
different clinical practices in different types of hospitals. The model has been set 
up with the possibility to customize each type of data, consumptions and unit 
costs. Results: We calculated the average (AVG) and the confidence interval (IC) 
for the incidence of each type of cost among the different surgical procedures. For 
the length of stay we observed the highest average incidence (35,1%; IC95% 24,4-
39,9), followed by the cost of materials with an average of 34,9% (IC95% 30,1-43,1), 
the operating room cost (avg 20,6%; IC95% 18,8-22,8), and the personnel (avg 9,4%; 
IC95% 7,2-11,1). cOnclusiOns: Through the Win-Win Model it is possible to ana-
lyze the costs of each type of surgical procedure and evaluate the economic impact 
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by the government budget. Results: Sixty-two DRGs were identified as suitable for 
day cases. The majority of these were procedures of the eye (16%), the ear, nose and 
throat (11.3%), the myoskeletal system (9.7%), the kidney and the urinary tract (9.7%) 
and the female reproductive system (9.7%). The hospital marginal cost of an increase 
in the length of stay by one day was estimated at 563.32 euros (95%CI: 541.6–585.1). 
The annual savings were estimated at 93.7 million euros for the SI and when labor 
opportunity cost is included the amount saved exceeds 225 million. cOnclusiOns: 
In light of the economic crisis and the continuously reduced health care budget, 
the health system should adopt cost-effective intervention in order to preserve a 
satisfactory level of health services output. As this study concludes, day surgery can 
save a great amount of resources and according to the international literature can 
also guarantee patients’ safety and satisfaction.
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Objectives: The Greek authorities implemented mandatory generic substitution 
trying to expand the use of generics, due to reasons of cost-containment. However, 
Greece lacks a strong, established generics culture. This study aims to investigate 
chronic patients’ perceptions on generics in Greece. MethOds: We carried out 
a cross-sectional study among 1600 patients from four chronic illness groups 
(HTN, Diabetes, COPD and Alzheimer mild to moderate stage). Logistic regression 
analysis was used to determine the factors associated with chronic patients’ per-
ceptions. Results: Of 1600 patients, 1594 responded to the survey (99.6%). Only 
67% has used generics in the past. 39.3% considers them safe, 34.3% thinks that 
the generics have the same quality standards as the originals and 37.3% believes 
that they have the same treatment outcomes. 63% expressed concern on potential 
adverse effects from generics. 58% argues that the drug’s country of origin affects its 
safety. Statistical analysis revealed that generics quality has a statistical significant 
relationship with patient’s income (OR 1.24; 95% CI 1.00-1.19), age (OR 0.99; 95% CI 
0.98-1.00), gender (OR 0.73; 95% CI 0.57-0.94) and health status (OR 1.00; 95% CI 1.00-
1.02) while generics effectiveness was positively related with the patient’s income 
(OR 1.10; 95% CI 1.02-1.20), gender (OR 0.70, 95% CI 0.55-0.90) and health (OR 1.00, 
95% CI 1.00-1.01). Women and the elderly are less likely to consider that the gener-
ics have the same standards as the originals. cOnclusiOns: Our findings reveal 
that chronic patients express reservations towards generic medicines which in an 
extent can probably explain the low generic market share in Greece. Perceptions 
about generics were found significant related mostly with patients’ demographic 
characteristic. The latter can be considered as useful information as it assists stake-
holders to identify on which chronic patients groups should direct campaigns in 
order to encourage generic drug use as a means to control expenditures and to save 
resources for innovative drugs.
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Objectives: To provide an overview of the Spanish generic medicines retail market 
and to identify policy measures which impede its development. Finally, recommen-
dations to increase both the efficiency of health care with regards to pharmaceuti-
cals in general and the sustainability of the Spanish generic medicines retail market 
are put forwards. MethOds: A literature review has been carried out to explore the 
current situation of the Spanish generic medicines market. In addition, a survey 
has been developed and interviews have been conducted to validate the infor-
mation obtained from the literature review. Results: The Spanish government’s 
focus on the price level of generic medicines in the past has decreased prices of 
generic medicines drastically. The current reference pricing system (since 2011) has 
eroded price differentials between originator and generic medicines in more than 
90% of the reference groups. Differing policies at the demand-side have resulted 
in differing generic market shares between the autonomous communities. Policies 
are needed to increase both the efficiency of the health care system with regards 
to pharmaceuticals (e.g. electronic prescribing, prescribing by international non-
proprietary name, etc.) and the sustainability of the Spanish generic medicines retail 
market (e.g. creating price difference between originator and generic medicines, 
accelerating market entrance, building and improving trust for generic medicines 
in patients and physicians, etc.). cOnclusiOns: The low volume of generic medi-
cines used in Spain combined with the continuous pressure on the price level of 
generic medicines threatens the sustainability of the generic medicines industry. 
The reduced price difference between originator and generic medicines tends to 
be an important barrier for the development of a generic medicines market. The 
unique experience in the Spanish market shows the importance of demand-side 
policies on the use of generic medicines.
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Objectives: When there are no direct head-to-head trials versus an appropriate 
comparator, indirect comparisons are commonly performed to support a clinical 
claim and relative pricing. In Australia, Public Summary Documents (PSDs), report-
ing on the Pharmaceutical Benefits Advisory Committee’s (PBAC) decision-making 
process relating to government reimbursement of medicines, have been published 
since July 2005. A review of PSDs specific to drugs where the primary claim was 
based on indirect evidence was undertaken to assess the success of the approach and 
mote its use. The audience includes those who develop, submit or use budget impact 
models and committees who evaluate reimbursement submissions. With a use 
of Guidelines for Pharmacoeconomic Evaluations, ISPOR Guidelines and proposed 
BIA template (which will be published in the updated version of the Guidelines for 
Pharmacoeconomic Evaluations) the quality of submissions to the HIF in Serbia 
would be raised and the decision time could be reduced.
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Objectives: The recent economic crisis has threatened the sustainability of many 
international economies as well as their health care systems. The objective of this 
paper was to quantify recent cost containment measures used to reduce Irish pub-
lic pharmaceutical expenditure in light of the ongoing fiscal restrain. MethOds: 
Pharmaceutical expenditure across the EU was briefly examined using the most 
current OECD data. The main pharmaceutical cost containment measures recently 
adopted in Ireland were identified under the headings of drug prices, fees/mark-ups 
and coverage/co-payments with full year 2011 public savings estimated. Results: 
EU pharmaceutical expenditure was estimated at € 190 billion in 2010, almost one 
fifth of all health expenditure. At € 528, Ireland spent more on pharmaceuticals 
than any other European country on a per capita basis and 50% more than the 
average across EU member states. Governments under pressure to maintain a sus-
tainable national health system and reduce deficits, while still preserving acute 
care levels, are cutting pharmaceutical expenditure. Many European countries, 
including Ireland, have increased the use of cost containment measures including 
a mix of price and volume controls. Collectively, these measures were estimated 
to have reduced Irish public pharmaceutical expenditure by € 380m in 2011. The 
main cost containment measures used involved addressing; 1) the ex-factory price 
of drugs including price cuts of up to 40% on off-patent and generic drugs leading 
to an estimated € 200m saving, 2) pharmacy dispensing fees and mark-ups via a 
new dispensing fee structure and reducing both retail and wholesale mark-ups 
with a € 100m saving, and 3) scheme coverage and patient co-payments including 
restricting scheme coverage for persons over 70 years and increasing the level of 
co-payments with savings of € 80m. cOnclusiOns: There use of pharmaceutical 
cost containment measures to decrease health expenditure is a trend that is likely 
to continue for some time yet.
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Objectives: Japan is now confronting budget constraints and trying to introduce 
economic evaluation into health care resource allocation. To clarify the basic atti-
tude towards health care resource allocation in Japanese people, a national survey 
was conducted. MethOds: A survey was carried out in a face-to-face manner with 
random sampling on the 50 municipalities in Japan, adjusting for age and sex, 
between March and April 2013. The questionnaire consisted of two scenarios; ques-
tion 1:”Imagine that there are two clinical examinations (A: less expensive with 
low power; B: more expensive with high power) and choose from the following two 
options: option 1: all subjects receive examination A and subsequently the death of 
1,000 people is prevented; option 2: a half of the subjects is selected by lottery and 
receives examination B, preventing the death of 1,100 people as a consequence.” ; 
question 2:” Imagine that two types of diseases differing the treatment cost(A: 10 
million per patient; B: 2 million per patient), and allocate 100 million yens to these 
diseases.” Results: Out of 1143 respondents, 601 chose the option 1 in question 1. 
In question 2, 217 chose the least utilitarian combination(A;8, B;10), 139 chose 2nd 
combination(A;6, B;20), 289 chose 3rd one(A;4, B;30), 67 chose 4th one(A;2, B;40), and 
379 chose the most utilitarian option(A;0, B;50). The weak correlation was observed 
in the utilitarian trend and age (r= 0.29, p < 0.01). Utilitarian tendency to maximize 
the health benefit varied among respondents with different educational back-
grounds. cOnclusiOns: We investigated the basic attitude towards health care 
resource allocation in Japanese people by answering to specific scenarios, which 
revealed fairly extreme utilitarian selection was the most popular. This utilitarian 
tendency correlated with age and education. It seems that the discussion on the 
priority setting in health care resource allocation in Japan based on this kind of 
empirical data become important.
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Objectives: Day surgery has been introduced in numerous heath care systems and 
has been proved able to save resources and promote efficiency and effectiveness. 
The aim of this study is to estimate the savings that can be realized by the adoption 
of day surgery by the Greek National Health System. MethOds: Surgery procedures 
were classified according to the type of anesthesia and the post-operative care they 
require. The procedures identified as suitable for day surgery, according to the above 
criteria, were matched to the Greek Diagnostics Related Groups (DRGs). The possible 
savings were calculated on the basis of the marginal cost these procedures impose 
to hospitals when treating them as inpatient surgeries. Savings were estimated for 
both the social insurance(SI) and for the government budget due to the fact that SI 
reimburses the capital production factor of each DRG while the labor cost is funded 
